These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27603206)

  • 21. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
    Karle J; Bolbrinker J; Vogl S; Kreutz R; Denkert C; Eucker J; Wischnewsky M; Possinger K; Regierer AC
    Breast Cancer Res Treat; 2013 Jun; 139(2):553-60. PubMed ID: 23686417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
    Seruga B; Amir E
    Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
    Wei X; Sun H; Zhuang J; Weng X; Zheng B; Lin Q; Zhang G; Cai J
    Clin Drug Investig; 2020 Jan; 40(1):25-32. PubMed ID: 31559573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
    Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
    Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment.
    Walko CM; McLeod H
    Pharmacogenomics; 2012 Apr; 13(6):691-7. PubMed ID: 22515611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
    Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
    Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
    Newman WG; Hadfield KD; Latif A; Roberts SA; Shenton A; McHague C; Lalloo F; Howell S; Evans DG
    Clin Cancer Res; 2008 Sep; 14(18):5913-8. PubMed ID: 18794105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
    Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
    J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
    Woods B; Veenstra D; Hawkins N
    Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
    Dieudonné AS; Lambrechts D; Claes B; Vandorpe T; Wildiers H; Timmerman D; Billen J; Leunen K; Amant F; Berteloot P; Smeets A; Paridaens R; Weltens C; Van Limbergen E; Van den Bogaert W; Vergote I; Van Huffel S; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 Dec; 118(3):531-8. PubMed ID: 19597703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
    Zembutsu H
    Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
    Lin G; Yi L; Zhang K; Wang L; Zhang R; Xie J; Li J
    PLoS One; 2015; 10(7):e0134174. PubMed ID: 26218263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.
    de Souza JA; Olopade OI
    Semin Oncol; 2011 Apr; 38(2):263-73. PubMed ID: 21421116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms.
    Fang H; Liu X; Ramírez J; Choudhury N; Kubo M; Im HK; Konkashbaev A; Cox NJ; Ratain MJ; Nakamura Y; O'Donnell PH
    Pharmacogenomics J; 2014 Dec; 14(6):564-72. PubMed ID: 24980783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.
    Peppercorn J; Hamilton E; Marcom PK; Beskow L; Lyman GH
    Cancer; 2013 Oct; 119(20):3703-9. PubMed ID: 23893861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
    Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
    Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
    Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
    Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.